Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOL1 | O14791 | 18/20 | 0.41 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30184356 | 1.00 | APOL1 (0.41) | APOL1EPAS1 | |
| SCHEMBL30184436 | 0.89 | APOL1 (0.49) | APOL1 | |
| SCHEMBL22160460 | 0.89 | APOL1 (0.49) | APOL1 | |
| SCHEMBL30337361 | 0.81 | APOL1 (0.38) | APOL1 | |
| SCHEMBL31312738 | 0.81 | APOL1 (0.43) | APOL1 | |
| SCHEMBL28974909 | 0.79 | APOL1 (0.53) | APOL1 | |
| SCHEMBL30325254 | 0.79 | APOL1 (0.53) | APOL1 | |
| SCHEMBL24099512 | 0.79 | APOL1 (0.56) | APOL1 | |
| SCHEMBL24098954 | 0.79 | APOL1 (0.56) | APOL1 | |
| SCHEMBL30325249 | 0.79 | APOL1 (0.53) | APOL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115867532-A | Inhibitors of APOL1 and uses thereof | 弗特克斯药品有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20230014907-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-01-19 | — | — | US | disclosed |
| WO-2021252849-A1 | INHIBITORS OF APOL1 AND USE OF THE SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230014907-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, APOB, NPC1L1 | APOL1 1/4885EPAS1 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.